Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1/2a multiple ascending dose intrathecal VO659 study in SCA1, SCA3, and Huntington's disease
MOH_2023-08-16_012816Phase 2Recruiting
- Sponsor
- Vico Therapeutics
- Start
- Jul 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of VO659 in spinocerebellar ataxia type 1 (SCA1), machado-joseph disease (MJD) and Huntington disease (HD) (5 arms), sponsored by Vico Therapeutics. Primary endpoint: Safety and tolerability of multiple ascending intrathecal doses of VO659. Started Jul 2023; status: recruiting.
02
Drugs
VO659
03
Conditions
spinocerebellar ataxia type 1 (SCA1)machado-joseph disease (MJD)Huntington disease (HD)
Beyond the preview
Go deeper on MOH_2023-08-16_012816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-16_012816.